 Alan Palestine
Concepts (671)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 68 | 2023 | 115 | 7.670 |
Why?
| | Panuveitis | 4 | 2023 | 6 | 3.270 |
Why?
| | Uveitis, Intermediate | 4 | 2023 | 7 | 2.400 |
Why?
| | Cataract | 6 | 2023 | 185 | 2.330 |
Why?
| | Fluocinolone Acetonide | 3 | 2023 | 16 | 2.300 |
Why?
| | Visual Acuity | 27 | 2024 | 274 | 2.290 |
Why?
| | Eye Infections, Bacterial | 5 | 2020 | 26 | 1.880 |
Why?
| | Retinopathy of Prematurity | 8 | 2020 | 111 | 1.860 |
Why?
| | Endophthalmitis | 6 | 2020 | 25 | 1.830 |
Why?
| | Glucocorticoids | 7 | 2023 | 532 | 1.810 |
Why?
| | Macular Edema | 5 | 2023 | 34 | 1.780 |
Why?
| | Scleritis | 3 | 2022 | 18 | 1.690 |
Why?
| | Vitrectomy | 8 | 2020 | 57 | 1.610 |
Why?
| | Corneal Ulcer | 2 | 2022 | 14 | 1.610 |
Why?
| | Macular Degeneration | 9 | 2023 | 152 | 1.520 |
Why?
| | Arthritis, Juvenile | 2 | 2022 | 42 | 1.320 |
Why?
| | Fluorescein Angiography | 14 | 2023 | 102 | 1.300 |
Why?
| | Vitreous Body | 15 | 2022 | 101 | 1.300 |
Why?
| | Ocular Hypertension | 4 | 2022 | 61 | 1.130 |
Why?
| | Postoperative Complications | 7 | 2021 | 2128 | 1.100 |
Why?
| | Cytomegalovirus Retinitis | 5 | 2022 | 17 | 1.070 |
Why?
| | Cyclosporins | 31 | 1991 | 58 | 1.030 |
Why?
| | Tomography, Optical Coherence | 5 | 2024 | 130 | 0.990 |
Why?
| | Glaucoma | 3 | 2023 | 202 | 0.980 |
Why?
| | Cataract Extraction | 4 | 2023 | 76 | 0.970 |
Why?
| | Drug Costs | 2 | 2016 | 92 | 0.940 |
Why?
| | Intraocular Pressure | 9 | 2022 | 276 | 0.920 |
Why?
| | Retinal Vessels | 6 | 2021 | 50 | 0.910 |
Why?
| | Geographic Atrophy | 5 | 2023 | 49 | 0.880 |
Why?
| | Inflammation | 10 | 2023 | 2480 | 0.880 |
Why?
| | Humans | 170 | 2024 | 114689 | 0.850 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2020 | 520 | 0.850 |
Why?
| | Uveitis, Posterior | 5 | 2019 | 12 | 0.850 |
Why?
| | Diabetic Retinopathy | 2 | 2022 | 149 | 0.850 |
Why?
| | Antirheumatic Agents | 2 | 2022 | 255 | 0.840 |
Why?
| | Anterior Chamber | 5 | 2021 | 19 | 0.840 |
Why?
| | Retinal Detachment | 3 | 2020 | 53 | 0.830 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 4 | 0.830 |
Why?
| | Eye Diseases | 10 | 2020 | 76 | 0.820 |
Why?
| | Retinitis | 15 | 1993 | 17 | 0.810 |
Why?
| | Methotrexate | 3 | 2022 | 226 | 0.810 |
Why?
| | Behcet Syndrome | 7 | 2021 | 16 | 0.790 |
Why?
| | Health Care Costs | 2 | 2016 | 381 | 0.790 |
Why?
| | Retinal Diseases | 6 | 2020 | 76 | 0.770 |
Why?
| | Corneal Transplantation | 4 | 2020 | 10 | 0.770 |
Why?
| | Acquired Immunodeficiency Syndrome | 22 | 1996 | 217 | 0.760 |
Why?
| | Retrospective Studies | 29 | 2024 | 12551 | 0.750 |
Why?
| | Retinal Vasculitis | 1 | 2021 | 7 | 0.750 |
Why?
| | Azathioprine | 2 | 2022 | 49 | 0.740 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.720 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 41 | 0.680 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 66 | 0.650 |
Why?
| | Homosexuality, Male | 1 | 2020 | 170 | 0.650 |
Why?
| | Practice Patterns, Physicians' | 3 | 2016 | 1177 | 0.630 |
Why?
| | Surveys and Questionnaires | 8 | 2022 | 4623 | 0.620 |
Why?
| | International Classification of Diseases | 1 | 2018 | 116 | 0.590 |
Why?
| | Cytomegalovirus | 3 | 2022 | 144 | 0.580 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 192 | 0.580 |
Why?
| | Sarcoidosis | 9 | 2023 | 135 | 0.560 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 497 | 0.560 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 34 | 0.560 |
Why?
| | Labor, Induced | 1 | 2017 | 32 | 0.560 |
Why?
| | Labor, Obstetric | 1 | 2017 | 52 | 0.550 |
Why?
| | Adult | 72 | 2024 | 30550 | 0.550 |
Why?
| | Retinal Drusen | 3 | 2021 | 25 | 0.540 |
Why?
| | Rheumatologists | 1 | 2016 | 12 | 0.540 |
Why?
| | Drug Implants | 5 | 2022 | 70 | 0.540 |
Why?
| | Ophthalmologists | 1 | 2016 | 12 | 0.540 |
Why?
| | Autoimmune Diseases | 20 | 2009 | 382 | 0.530 |
Why?
| | Conjunctivitis | 2 | 2015 | 17 | 0.530 |
Why?
| | Polychondritis, Relapsing | 1 | 2015 | 2 | 0.520 |
Why?
| | Insurance, Health | 2 | 2016 | 244 | 0.520 |
Why?
| | Female | 99 | 2024 | 59511 | 0.520 |
Why?
| | Ear Auricle | 1 | 2015 | 11 | 0.520 |
Why?
| | Vision Disorders | 2 | 2016 | 130 | 0.510 |
Why?
| | Male | 82 | 2024 | 55599 | 0.500 |
Why?
| | Neonatal Screening | 4 | 2018 | 152 | 0.490 |
Why?
| | Wet Macular Degeneration | 3 | 2020 | 32 | 0.490 |
Why?
| | Surgical Wound Infection | 1 | 2018 | 248 | 0.490 |
Why?
| | Needles | 1 | 2015 | 49 | 0.490 |
Why?
| | Biopsy, Needle | 1 | 2015 | 182 | 0.480 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 900 | 0.480 |
Why?
| | Aged | 39 | 2024 | 19074 | 0.480 |
Why?
| | Middle Aged | 53 | 2024 | 26737 | 0.470 |
Why?
| | DNA, Viral | 1 | 2016 | 350 | 0.470 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1003 | 0.460 |
Why?
| | Premature Birth | 1 | 2017 | 276 | 0.450 |
Why?
| | Databases, Factual | 1 | 2018 | 1125 | 0.450 |
Why?
| | Complement Activation | 3 | 2022 | 340 | 0.440 |
Why?
| | Follow-Up Studies | 12 | 2021 | 4411 | 0.430 |
Why?
| | Melanoma | 1 | 2019 | 620 | 0.430 |
Why?
| | Vaccination | 1 | 2021 | 1204 | 0.420 |
Why?
| | Bacteria | 2 | 2018 | 725 | 0.420 |
Why?
| | Gestational Age | 8 | 2020 | 760 | 0.420 |
Why?
| | Immunosuppressive Agents | 5 | 2022 | 646 | 0.420 |
Why?
| | Ophthalmology | 3 | 2022 | 77 | 0.410 |
Why?
| | Antiviral Agents | 11 | 2022 | 645 | 0.410 |
Why?
| | Cytomegalovirus Infections | 12 | 1999 | 180 | 0.410 |
Why?
| | Skin Neoplasms | 2 | 2019 | 756 | 0.400 |
Why?
| | Placenta | 1 | 2018 | 626 | 0.400 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 1879 | 0.400 |
Why?
| | Steroids | 2 | 2023 | 144 | 0.390 |
Why?
| | Electronic Health Records | 1 | 2018 | 800 | 0.390 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1481 | 0.380 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2022 | 116 | 0.370 |
Why?
| | Colorado | 9 | 2022 | 4099 | 0.360 |
Why?
| | Macula Lutea | 3 | 2020 | 15 | 0.360 |
Why?
| | Registries | 4 | 2023 | 1768 | 0.350 |
Why?
| | Ciliary Body | 9 | 2018 | 33 | 0.350 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1395 | 0.350 |
Why?
| | Trabeculectomy | 2 | 2022 | 65 | 0.350 |
Why?
| | Chorioretinitis | 3 | 2024 | 4 | 0.340 |
Why?
| | Complement Factor B | 2 | 2022 | 100 | 0.340 |
Why?
| | United States | 11 | 2023 | 12183 | 0.330 |
Why?
| | Aged, 80 and over | 12 | 2021 | 6347 | 0.330 |
Why?
| | Ganciclovir | 9 | 2022 | 49 | 0.330 |
Why?
| | Glaucoma, Open-Angle | 2 | 2022 | 95 | 0.320 |
Why?
| | Antigens | 14 | 1990 | 318 | 0.310 |
Why?
| | Aqueous Humor | 4 | 2022 | 31 | 0.310 |
Why?
| | Complement System Proteins | 3 | 2022 | 283 | 0.310 |
Why?
| | Adolescent | 28 | 2024 | 17848 | 0.300 |
Why?
| | Eye Proteins | 7 | 1990 | 70 | 0.300 |
Why?
| | Conjunctival Diseases | 3 | 2017 | 17 | 0.290 |
Why?
| | Cyclosporine | 2 | 2022 | 161 | 0.290 |
Why?
| | Retina | 18 | 1993 | 263 | 0.290 |
Why?
| | Birth Weight | 4 | 2020 | 440 | 0.280 |
Why?
| | Uveitis, Anterior | 4 | 2018 | 11 | 0.270 |
Why?
| | Corneal Diseases | 5 | 2017 | 33 | 0.270 |
Why?
| | Child | 21 | 2022 | 18415 | 0.270 |
Why?
| | Incidence | 6 | 2021 | 2313 | 0.270 |
Why?
| | Opportunistic Infections | 4 | 1991 | 43 | 0.250 |
Why?
| | Risk Factors | 10 | 2020 | 8632 | 0.250 |
Why?
| | Adalimumab | 2 | 2022 | 44 | 0.250 |
Why?
| | Biological Factors | 2 | 2022 | 35 | 0.250 |
Why?
| | Fundus Oculi | 7 | 2021 | 40 | 0.250 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 45 | 0.250 |
Why?
| | Bromocriptine | 4 | 1990 | 26 | 0.250 |
Why?
| | Time Factors | 12 | 2021 | 6116 | 0.250 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 4410 | 0.240 |
Why?
| | Infant | 9 | 2022 | 7963 | 0.240 |
Why?
| | Young Adult | 7 | 2024 | 10470 | 0.240 |
Why?
| | Laser Therapy | 5 | 2021 | 100 | 0.240 |
Why?
| | Specialization | 2 | 2016 | 115 | 0.230 |
Why?
| | Papilledema | 2 | 2024 | 40 | 0.230 |
Why?
| | Infant, Premature | 2 | 2019 | 476 | 0.230 |
Why?
| | Child, Preschool | 9 | 2022 | 9116 | 0.230 |
Why?
| | Cohort Studies | 7 | 2020 | 4895 | 0.230 |
Why?
| | Retinal Vein Occlusion | 1 | 2004 | 13 | 0.230 |
Why?
| | Quality of Life | 3 | 2023 | 2353 | 0.220 |
Why?
| | Mycophenolic Acid | 2 | 2022 | 77 | 0.220 |
Why?
| | Fluoresceins | 5 | 1989 | 46 | 0.220 |
Why?
| | Algorithms | 4 | 2018 | 1469 | 0.220 |
Why?
| | Choroid | 11 | 2021 | 47 | 0.210 |
Why?
| | Phacoemulsification | 3 | 2019 | 107 | 0.210 |
Why?
| | Infant, Very Low Birth Weight | 3 | 2018 | 66 | 0.210 |
Why?
| | Anti-Inflammatory Agents | 3 | 2022 | 447 | 0.210 |
Why?
| | Etanercept | 1 | 2022 | 51 | 0.210 |
Why?
| | Histocompatibility Antigens Class II | 9 | 1994 | 352 | 0.210 |
Why?
| | Foscarnet | 4 | 1996 | 18 | 0.200 |
Why?
| | Eye Neoplasms | 3 | 2017 | 16 | 0.200 |
Why?
| | Reference Standards | 2 | 2022 | 159 | 0.200 |
Why?
| | Antibodies, Monoclonal | 12 | 2020 | 1262 | 0.190 |
Why?
| | Tacrolimus | 1 | 2022 | 134 | 0.190 |
Why?
| | Albumins | 1 | 2022 | 89 | 0.190 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.190 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 10 | 0.190 |
Why?
| | Graft Rejection | 3 | 2021 | 513 | 0.190 |
Why?
| | Eye Infections, Viral | 2 | 1991 | 7 | 0.190 |
Why?
| | Capsule Opacification | 1 | 2021 | 20 | 0.190 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 1693 | 0.190 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.190 |
Why?
| | Rats, Inbred Lew | 18 | 1994 | 91 | 0.190 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.180 |
Why?
| | T-Lymphocytes, Helper-Inducer | 8 | 1994 | 127 | 0.180 |
Why?
| | Laser Coagulation | 2 | 2018 | 54 | 0.180 |
Why?
| | Retinal Pigment Epithelium | 1 | 2021 | 58 | 0.180 |
Why?
| | Anemia, Sickle Cell | 1 | 2004 | 215 | 0.180 |
Why?
| | Treatment Outcome | 9 | 2022 | 9088 | 0.180 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2020 | 16 | 0.180 |
Why?
| | Infant, Newborn | 7 | 2020 | 5047 | 0.170 |
Why?
| | Multiple Sclerosis | 3 | 2023 | 376 | 0.170 |
Why?
| | Administration, Topical | 4 | 2016 | 138 | 0.170 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 20 | 0.170 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.170 |
Why?
| | Endotoxins | 3 | 1991 | 211 | 0.170 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 36 | 0.170 |
Why?
| | Canada | 1 | 2020 | 322 | 0.170 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 176 | 0.170 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 33 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1140 | 0.160 |
Why?
| | Complement C3a | 1 | 2019 | 33 | 0.160 |
Why?
| | Pyrimidinones | 1 | 2019 | 88 | 0.160 |
Why?
| | Acyclovir | 5 | 2001 | 100 | 0.160 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 182 | 0.160 |
Why?
| | Decision Making | 2 | 2016 | 782 | 0.160 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 116 | 0.160 |
Why?
| | Organ Transplantation | 1 | 2021 | 159 | 0.160 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 44 | 0.160 |
Why?
| | Computer Systems | 1 | 2018 | 45 | 0.150 |
Why?
| | Viral Load | 2 | 2016 | 405 | 0.150 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.150 |
Why?
| | Biological Products | 1 | 2021 | 166 | 0.150 |
Why?
| | Organophosphonates | 1 | 1998 | 90 | 0.150 |
Why?
| | Intravitreal Injections | 1 | 2018 | 45 | 0.150 |
Why?
| | Metformin | 1 | 2021 | 276 | 0.150 |
Why?
| | Disease-Free Survival | 1 | 2019 | 620 | 0.150 |
Why?
| | Risk | 4 | 2018 | 812 | 0.150 |
Why?
| | Reoperation | 1 | 2020 | 514 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1214 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 178 | 0.140 |
Why?
| | Farber Lipogranulomatosis | 1 | 2017 | 4 | 0.140 |
Why?
| | Synovitis | 1 | 2017 | 24 | 0.140 |
Why?
| | Amnion | 1 | 2017 | 24 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2022 | 322 | 0.140 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2017 | 34 | 0.140 |
Why?
| | Parity | 1 | 2017 | 98 | 0.140 |
Why?
| | Arrestin | 13 | 1990 | 13 | 0.140 |
Why?
| | Cicatrix | 1 | 2017 | 50 | 0.140 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 30 | 0.140 |
Why?
| | Medical Informatics | 1 | 2017 | 90 | 0.140 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 993 | 0.130 |
Why?
| | Herpes Zoster | 2 | 2009 | 331 | 0.130 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 125 | 0.130 |
Why?
| | T-Lymphocytes | 12 | 2022 | 1737 | 0.130 |
Why?
| | Terminology as Topic | 1 | 2017 | 187 | 0.130 |
Why?
| | Arthritis | 1 | 2017 | 109 | 0.130 |
Why?
| | Lymphocytes | 9 | 1991 | 330 | 0.130 |
Why?
| | Pregnancy | 2 | 2018 | 5518 | 0.130 |
Why?
| | Transplantation, Homologous | 2 | 2016 | 377 | 0.130 |
Why?
| | Recovery of Function | 1 | 2019 | 574 | 0.130 |
Why?
| | Weight Gain | 2 | 2016 | 453 | 0.130 |
Why?
| | Disease Management | 1 | 2019 | 560 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 152 | 0.130 |
Why?
| | Endoscopy | 1 | 2018 | 246 | 0.130 |
Why?
| | Microbiological Techniques | 1 | 2015 | 29 | 0.120 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 111 | 0.120 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 286 | 0.120 |
Why?
| | Rats | 24 | 1994 | 4958 | 0.120 |
Why?
| | Rheumatology | 1 | 2016 | 88 | 0.120 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 137 | 0.120 |
Why?
| | Lymphocyte Activation | 8 | 1990 | 1037 | 0.120 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 329 | 0.120 |
Why?
| | Phosphonoacetic Acid | 2 | 1991 | 10 | 0.120 |
Why?
| | Prospective Studies | 6 | 2020 | 6220 | 0.120 |
Why?
| | Reproducibility of Results | 2 | 2018 | 2765 | 0.120 |
Why?
| | Health Care Surveys | 1 | 2016 | 539 | 0.110 |
Why?
| | Physicians | 1 | 2022 | 772 | 0.110 |
Why?
| | Fetus | 1 | 2018 | 700 | 0.110 |
Why?
| | Toxoplasmosis, Ocular | 2 | 1994 | 2 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 268 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 785 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 1998 | 959 | 0.110 |
Why?
| | Lymphoma, B-Cell | 2 | 1993 | 86 | 0.110 |
Why?
| | Research Design | 1 | 2019 | 928 | 0.110 |
Why?
| | Kidney Diseases | 6 | 1989 | 350 | 0.110 |
Why?
| | HIV-1 | 1 | 1998 | 768 | 0.110 |
Why?
| | Creatinine | 7 | 1992 | 425 | 0.100 |
Why?
| | Risk Assessment | 2 | 2019 | 2968 | 0.100 |
Why?
| | Patient Selection | 1 | 2016 | 641 | 0.100 |
Why?
| | Health Surveys | 1 | 2014 | 443 | 0.100 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 1992 | 98 | 0.100 |
Why?
| | Mothers | 1 | 2018 | 651 | 0.100 |
Why?
| | Iris | 3 | 1991 | 19 | 0.100 |
Why?
| | HLA Antigens | 7 | 1991 | 225 | 0.100 |
Why?
| | Biomarkers | 5 | 2023 | 3408 | 0.100 |
Why?
| | Pars Planitis | 1 | 1992 | 1 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1355 | 0.100 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 1991 | 9 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 517 | 0.100 |
Why?
| | Injections, Intravenous | 7 | 1999 | 198 | 0.090 |
Why?
| | Clinical Competence | 1 | 2018 | 893 | 0.090 |
Why?
| | Capillary Permeability | 2 | 1991 | 139 | 0.090 |
Why?
| | HIV | 4 | 2020 | 208 | 0.090 |
Why?
| | Bacterial Infections | 3 | 1989 | 218 | 0.090 |
Why?
| | Toxoplasma | 2 | 1994 | 31 | 0.090 |
Why?
| | Antigens, Surface | 3 | 1989 | 146 | 0.090 |
Why?
| | Cytophagaceae | 1 | 1990 | 1 | 0.090 |
Why?
| | Capnocytophaga | 1 | 1990 | 2 | 0.090 |
Why?
| | Granuloma | 4 | 2023 | 83 | 0.090 |
Why?
| | Animals | 34 | 2021 | 31706 | 0.080 |
Why?
| | Urine | 1 | 1989 | 54 | 0.080 |
Why?
| | Antigens, Protozoan | 1 | 1989 | 19 | 0.080 |
Why?
| | Sebaceous Gland Neoplasms | 1 | 1989 | 2 | 0.080 |
Why?
| | Odds Ratio | 4 | 2019 | 953 | 0.080 |
Why?
| | Eyelid Neoplasms | 1 | 1989 | 8 | 0.080 |
Why?
| | Blood Chemical Analysis | 1 | 1989 | 90 | 0.080 |
Why?
| | Drug Therapy, Combination | 5 | 1998 | 951 | 0.080 |
Why?
| | Tonometry, Ocular | 2 | 2019 | 83 | 0.080 |
Why?
| | Eye | 7 | 1988 | 98 | 0.080 |
Why?
| | Postoperative Period | 2 | 2019 | 289 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2019 | 797 | 0.070 |
Why?
| | Antibody Formation | 3 | 1985 | 266 | 0.070 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1987 | 14 | 0.070 |
Why?
| | Escherichia coli | 1 | 1991 | 720 | 0.070 |
Why?
| | Autoantibodies | 6 | 1992 | 1346 | 0.070 |
Why?
| | Dextrans | 1 | 1987 | 73 | 0.070 |
Why?
| | Fanconi Syndrome | 1 | 1986 | 2 | 0.070 |
Why?
| | Cell Movement | 2 | 1988 | 869 | 0.070 |
Why?
| | Prednisolone | 2 | 2020 | 75 | 0.070 |
Why?
| | Phenotype | 4 | 2022 | 2796 | 0.070 |
Why?
| | Lymphocyte Transfusion | 1 | 1986 | 19 | 0.070 |
Why?
| | Immunoenzyme Techniques | 8 | 1991 | 192 | 0.070 |
Why?
| | Infliximab | 2 | 2021 | 94 | 0.060 |
Why?
| | Interferometry | 1 | 1985 | 4 | 0.060 |
Why?
| | Lasers | 2 | 1985 | 121 | 0.060 |
Why?
| | Lenses, Intraocular | 2 | 2021 | 42 | 0.060 |
Why?
| | Panophthalmitis | 1 | 1985 | 2 | 0.060 |
Why?
| | Uveomeningoencephalitic Syndrome | 3 | 1990 | 6 | 0.060 |
Why?
| | Protein S Deficiency | 1 | 2004 | 6 | 0.060 |
Why?
| | Choroiditis | 4 | 1991 | 6 | 0.060 |
Why?
| | Biopsy | 5 | 1993 | 1036 | 0.060 |
Why?
| | Myopia | 1 | 1984 | 36 | 0.060 |
Why?
| | Microscopy, Electron | 8 | 1988 | 410 | 0.060 |
Why?
| | Optic Disk | 1 | 2024 | 38 | 0.050 |
Why?
| | Tears | 4 | 1987 | 14 | 0.050 |
Why?
| | Tretinoin | 1 | 1984 | 122 | 0.050 |
Why?
| | Phagocyte Bactericidal Dysfunction | 1 | 1983 | 12 | 0.050 |
Why?
| | Retinal Artery | 2 | 1987 | 15 | 0.050 |
Why?
| | Ophthalmia, Sympathetic | 3 | 1990 | 3 | 0.050 |
Why?
| | Keratoplasty, Penetrating | 2 | 1994 | 4 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2020 | 3003 | 0.050 |
Why?
| | Immunologic Memory | 1 | 1985 | 313 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 206 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 1989 | 795 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Immunohistochemistry | 6 | 1993 | 1629 | 0.050 |
Why?
| | Deltaretrovirus | 3 | 1986 | 12 | 0.050 |
Why?
| | Aneurysm | 1 | 1982 | 29 | 0.050 |
Why?
| | Cavernous Sinus | 1 | 1981 | 14 | 0.050 |
Why?
| | 2-Aminopurine | 1 | 2001 | 10 | 0.050 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2001 | 5 | 0.050 |
Why?
| | Infusions, Intravenous | 2 | 2020 | 371 | 0.050 |
Why?
| | Arteriovenous Fistula | 1 | 1981 | 29 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 154 | 0.050 |
Why?
| | Transplantation Tolerance | 1 | 2021 | 30 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 1991 | 3535 | 0.050 |
Why?
| | Abatacept | 1 | 2021 | 40 | 0.050 |
Why?
| | Kidney | 3 | 1989 | 1188 | 0.050 |
Why?
| | Pigment Epithelium of Eye | 4 | 1990 | 34 | 0.050 |
Why?
| | Tertiary Healthcare | 1 | 2020 | 29 | 0.050 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 50 | 0.050 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 8 | 0.040 |
Why?
| | Gonioscopy | 1 | 2020 | 6 | 0.040 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 14 | 0.040 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 25 | 0.040 |
Why?
| | Amyloidosis | 1 | 2020 | 36 | 0.040 |
Why?
| | Carotid Arteries | 1 | 1981 | 180 | 0.040 |
Why?
| | Epithelium | 6 | 1991 | 295 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 220 | 0.040 |
Why?
| | Hypertension | 5 | 1991 | 1056 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 550 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 87 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 287 | 0.040 |
Why?
| | Immunization, Passive | 3 | 1988 | 73 | 0.040 |
Why?
| | Cornea | 4 | 1989 | 102 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 362 | 0.040 |
Why?
| | Sarcoma, Kaposi | 4 | 1999 | 68 | 0.040 |
Why?
| | Cytosine | 1 | 1998 | 44 | 0.040 |
Why?
| | Trabecular Meshwork | 1 | 2019 | 77 | 0.040 |
Why?
| | Logistic Models | 2 | 2019 | 1841 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 257 | 0.040 |
Why?
| | Prolactin | 2 | 1988 | 96 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2020 | 411 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 72 | 0.040 |
Why?
| | Conjunctiva | 3 | 1989 | 51 | 0.040 |
Why?
| | Retinol-Binding Proteins | 2 | 1988 | 13 | 0.040 |
Why?
| | Fluorometholone | 1 | 2017 | 4 | 0.040 |
Why?
| | Administration, Oral | 3 | 1999 | 728 | 0.040 |
Why?
| | Group Processes | 1 | 2017 | 53 | 0.040 |
Why?
| | Drug Evaluation | 2 | 1988 | 77 | 0.040 |
Why?
| | North America | 1 | 2018 | 256 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2022 | 641 | 0.040 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2017 | 30 | 0.040 |
Why?
| | Chemotaxis, Leukocyte | 2 | 1987 | 130 | 0.030 |
Why?
| | Interferon-gamma | 2 | 1991 | 719 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 296 | 0.030 |
Why?
| | HLA-DR Antigens | 5 | 1991 | 219 | 0.030 |
Why?
| | Cattle | 5 | 1991 | 920 | 0.030 |
Why?
| | Properdin | 1 | 1976 | 8 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 442 | 0.030 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 15 | 0.030 |
Why?
| | Rats, Inbred Strains | 5 | 1987 | 362 | 0.030 |
Why?
| | Plasma Cells | 2 | 1987 | 56 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 1996 | 66 | 0.030 |
Why?
| | Proteins | 2 | 2020 | 908 | 0.030 |
Why?
| | Chronic Disease | 4 | 1990 | 1578 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 523 | 0.030 |
Why?
| | Magnesium | 2 | 1986 | 145 | 0.030 |
Why?
| | HIV Infections | 1 | 2009 | 2469 | 0.030 |
Why?
| | Syndrome | 2 | 1987 | 333 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1430 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 4 | 1988 | 1842 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 176 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 836 | 0.030 |
Why?
| | Glycoproteins | 1 | 1976 | 304 | 0.030 |
Why?
| | Blood Proteins | 2 | 1989 | 231 | 0.030 |
Why?
| | Recurrence | 2 | 1988 | 935 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 1988 | 1342 | 0.030 |
Why?
| | Conjunctival Neoplasms | 2 | 1984 | 7 | 0.030 |
Why?
| | Retinal Hemorrhage | 2 | 1986 | 18 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1013 | 0.030 |
Why?
| | Models, Biological | 2 | 2016 | 1621 | 0.030 |
Why?
| | Granulomatous Disease, Chronic | 2 | 1983 | 60 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 1994 | 339 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 4 | 1989 | 397 | 0.030 |
Why?
| | Antibodies, Antinuclear | 2 | 1992 | 58 | 0.030 |
Why?
| | Immunity, Cellular | 2 | 1985 | 248 | 0.030 |
Why?
| | Immunization | 2 | 1985 | 397 | 0.030 |
Why?
| | Cells, Cultured | 5 | 1991 | 3886 | 0.030 |
Why?
| | Dinoprostone | 2 | 1990 | 184 | 0.030 |
Why?
| | Models, Statistical | 1 | 2016 | 599 | 0.030 |
Why?
| | Cell Line | 5 | 1991 | 2637 | 0.020 |
Why?
| | Eye Infections | 1 | 1992 | 2 | 0.020 |
Why?
| | Sepsis | 2 | 1984 | 509 | 0.020 |
Why?
| | Kinetics | 2 | 1988 | 1551 | 0.020 |
Why?
| | Epitopes | 3 | 1990 | 435 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 84 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2540 | 0.020 |
Why?
| | Propionibacterium acnes | 1 | 1991 | 8 | 0.020 |
Why?
| | Indomethacin | 2 | 1990 | 70 | 0.020 |
Why?
| | Transforming Growth Factor beta | 2 | 1991 | 448 | 0.020 |
Why?
| | B-Lymphocytes | 2 | 1987 | 766 | 0.020 |
Why?
| | Dogs | 2 | 1990 | 334 | 0.020 |
Why?
| | Biological Transport, Active | 1 | 1991 | 71 | 0.020 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 1990 | 6 | 0.020 |
Why?
| | Microcirculation | 1 | 1991 | 135 | 0.020 |
Why?
| | Random Allocation | 2 | 1988 | 335 | 0.020 |
Why?
| | Protein Binding | 2 | 1989 | 1890 | 0.020 |
Why?
| | Coronary Circulation | 1 | 1991 | 133 | 0.020 |
Why?
| | Cefazolin | 1 | 1990 | 18 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 1991 | 1230 | 0.020 |
Why?
| | Endothelium, Corneal | 1 | 1990 | 15 | 0.020 |
Why?
| | Flow Cytometry | 2 | 1992 | 1083 | 0.020 |
Why?
| | Fluorescein | 1 | 1989 | 25 | 0.020 |
Why?
| | Keratitis | 2 | 1994 | 11 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 1990 | 149 | 0.020 |
Why?
| | Kidney Function Tests | 2 | 1989 | 140 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 1989 | 173 | 0.020 |
Why?
| | Retroviridae Proteins | 1 | 1989 | 11 | 0.020 |
Why?
| | Hemocyanins | 2 | 1988 | 55 | 0.020 |
Why?
| | Antimetabolites | 1 | 1989 | 21 | 0.020 |
Why?
| | Alkylating Agents | 1 | 1989 | 27 | 0.020 |
Why?
| | Heptanoates | 1 | 1988 | 2 | 0.020 |
Why?
| | Drug Eruptions | 1 | 1989 | 26 | 0.020 |
Why?
| | Interferon Type I | 1 | 1990 | 128 | 0.020 |
Why?
| | Lung Diseases | 2 | 1986 | 701 | 0.020 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1989 | 24 | 0.020 |
Why?
| | Candidiasis | 1 | 1989 | 51 | 0.020 |
Why?
| | Suramin | 1 | 1988 | 6 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 1989 | 56 | 0.020 |
Why?
| | Receptors, Virus | 1 | 1989 | 75 | 0.020 |
Why?
| | Toxoplasmosis | 1 | 1989 | 31 | 0.020 |
Why?
| | Lens, Crystalline | 1 | 1990 | 90 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 1988 | 60 | 0.020 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 1989 | 82 | 0.020 |
Why?
| | Dexamethasone | 2 | 1987 | 317 | 0.020 |
Why?
| | Corneal Injuries | 1 | 1989 | 33 | 0.020 |
Why?
| | Injections | 1 | 1989 | 159 | 0.020 |
Why?
| | Mycobacterium Infections | 1 | 1989 | 61 | 0.020 |
Why?
| | Placebos | 1 | 1988 | 197 | 0.020 |
Why?
| | Central Nervous System Diseases | 1 | 1989 | 61 | 0.020 |
Why?
| | Antigen-Antibody Complex | 2 | 1985 | 84 | 0.020 |
Why?
| | HIV Seropositivity | 1 | 1989 | 109 | 0.020 |
Why?
| | Sugar Alcohol Dehydrogenases | 1 | 1987 | 2 | 0.020 |
Why?
| | Imidazolidines | 1 | 1987 | 8 | 0.020 |
Why?
| | Elapid Venoms | 1 | 1987 | 15 | 0.020 |
Why?
| | Galactosemias | 1 | 1987 | 8 | 0.020 |
Why?
| | Colchicine | 1 | 1987 | 24 | 0.020 |
Why?
| | Pituitary-Adrenal System | 1 | 1989 | 130 | 0.020 |
Why?
| | Blood-Retinal Barrier | 1 | 1987 | 13 | 0.020 |
Why?
| | Community Health Services | 1 | 2009 | 212 | 0.020 |
Why?
| | Aldehyde Reductase | 1 | 1987 | 24 | 0.020 |
Why?
| | Prednisone | 2 | 1986 | 229 | 0.020 |
Why?
| | Specific Gravity | 1 | 1987 | 11 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 1 | 1987 | 64 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 1987 | 79 | 0.020 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 1987 | 6 | 0.020 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1989 | 164 | 0.020 |
Why?
| | Herpesviridae Infections | 1 | 1989 | 138 | 0.020 |
Why?
| | Drug Interactions | 1 | 1989 | 338 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 594 | 0.020 |
Why?
| | Onchocerciasis | 1 | 1987 | 7 | 0.020 |
Why?
| | Heart Rate | 1 | 1991 | 709 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 1990 | 493 | 0.020 |
Why?
| | Organ Specificity | 1 | 1987 | 268 | 0.020 |
Why?
| | Molecular Weight | 1 | 1987 | 331 | 0.020 |
Why?
| | Macaca mulatta | 1 | 1987 | 131 | 0.020 |
Why?
| | Sclera | 1 | 1987 | 35 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 1990 | 823 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3346 | 0.020 |
Why?
| | Wound Healing | 1 | 1989 | 258 | 0.020 |
Why?
| | Dihydroergotoxine | 1 | 1986 | 1 | 0.020 |
Why?
| | Imidazoles | 1 | 1987 | 208 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1987 | 201 | 0.020 |
Why?
| | Indium | 1 | 1986 | 8 | 0.020 |
Why?
| | Radioisotopes | 1 | 1986 | 28 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 1986 | 23 | 0.020 |
Why?
| | Muramidase | 1 | 1986 | 72 | 0.020 |
Why?
| | Immune Tolerance | 1 | 1988 | 323 | 0.020 |
Why?
| | Prognosis | 2 | 1985 | 3329 | 0.020 |
Why?
| | Reference Values | 4 | 1989 | 743 | 0.020 |
Why?
| | Serum Albumin | 1 | 1986 | 137 | 0.020 |
Why?
| | Double-Blind Method | 3 | 2001 | 1660 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 666 | 0.020 |
Why?
| | Osteoporosis | 1 | 1989 | 226 | 0.020 |
Why?
| | Acute Disease | 2 | 1987 | 911 | 0.020 |
Why?
| | Vascular Diseases | 1 | 1988 | 230 | 0.020 |
Why?
| | Connective Tissue | 1 | 1985 | 36 | 0.020 |
Why?
| | Rabbits | 1 | 1986 | 733 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 1992 | 2387 | 0.020 |
Why?
| | Pigmentation Disorders | 1 | 1985 | 7 | 0.020 |
Why?
| | Tetanus Toxoid | 1 | 1985 | 37 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1985 | 286 | 0.020 |
Why?
| | Salmonella typhimurium | 1 | 1986 | 164 | 0.020 |
Why?
| | Fibrosis | 1 | 1987 | 453 | 0.020 |
Why?
| | Antibodies | 1 | 1987 | 371 | 0.020 |
Why?
| | Retinitis Pigmentosa | 1 | 1984 | 16 | 0.020 |
Why?
| | Potassium | 1 | 1985 | 128 | 0.020 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 1 | 1984 | 2 | 0.010 |
Why?
| | Lymphadenitis | 1 | 1984 | 4 | 0.010 |
Why?
| | Kidney Glomerulus | 1 | 1985 | 100 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2009 | 635 | 0.010 |
Why?
| | Blood Sedimentation | 1 | 1984 | 32 | 0.010 |
Why?
| | Chlorides | 1 | 1985 | 127 | 0.010 |
Why?
| | Kidney Tubules, Proximal | 1 | 1985 | 113 | 0.010 |
Why?
| | Peptides | 1 | 1990 | 848 | 0.010 |
Why?
| | Isotretinoin | 1 | 1984 | 22 | 0.010 |
Why?
| | Oculomotor Muscles | 1 | 1984 | 40 | 0.010 |
Why?
| | Acne Vulgaris | 1 | 1984 | 20 | 0.010 |
Why?
| | Complement C3 | 1 | 1985 | 188 | 0.010 |
Why?
| | Uveal Diseases | 1 | 1983 | 5 | 0.010 |
Why?
| | Optic Neuritis | 1 | 1984 | 37 | 0.010 |
Why?
| | Carbon Dioxide | 1 | 1985 | 218 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 1989 | 489 | 0.010 |
Why?
| | Uric Acid | 1 | 1984 | 148 | 0.010 |
Why?
| | Chediak-Higashi Syndrome | 1 | 1983 | 7 | 0.010 |
Why?
| | Anemia | 1 | 1984 | 143 | 0.010 |
Why?
| | Rats, Inbred BN | 2 | 1994 | 52 | 0.010 |
Why?
| | Liver Diseases | 1 | 1986 | 255 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1984 | 125 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1986 | 1121 | 0.010 |
Why?
| | Liver | 1 | 1990 | 1637 | 0.010 |
Why?
| | Fluorometry | 1 | 1981 | 19 | 0.010 |
Why?
| | Immunochemistry | 3 | 1986 | 11 | 0.010 |
Why?
| | Melanosis | 1 | 1981 | 13 | 0.010 |
Why?
| | Computers | 1 | 1981 | 60 | 0.010 |
Why?
| | Histocytochemistry | 3 | 1986 | 78 | 0.010 |
Why?
| | Eyelid Diseases | 1 | 1981 | 21 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1985 | 770 | 0.010 |
Why?
| | Edema | 1 | 1982 | 119 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1108 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2001 | 305 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1994 | 154 | 0.010 |
Why?
| | HLA-DQ Antigens | 2 | 1991 | 174 | 0.010 |
Why?
| | Protease Inhibitors | 1 | 1999 | 97 | 0.010 |
Why?
| | Permeability | 2 | 1987 | 149 | 0.010 |
Why?
| | Arthus Reaction | 2 | 1987 | 9 | 0.010 |
Why?
| | Sucrose | 2 | 1987 | 92 | 0.010 |
Why?
| | Photoreceptor Cells | 2 | 1987 | 12 | 0.010 |
Why?
| | Macrophages | 2 | 1994 | 1263 | 0.010 |
Why?
| | Survival Analysis | 1 | 1999 | 1211 | 0.010 |
Why?
| | Immunologic Techniques | 2 | 1986 | 39 | 0.010 |
Why?
| | Tissue Donors | 2 | 1989 | 316 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 1994 | 17 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1994 | 68 | 0.010 |
Why?
| | DNA, Protozoan | 1 | 1994 | 26 | 0.010 |
Why?
| | Shock, Septic | 1 | 1976 | 186 | 0.010 |
Why?
| | Eye Enucleation | 1 | 1993 | 12 | 0.010 |
Why?
| | Viral Proteins | 2 | 1985 | 281 | 0.010 |
Why?
| | Mice | 2 | 1986 | 14869 | 0.010 |
Why?
| | Didanosine | 1 | 1993 | 13 | 0.010 |
Why?
| | Zidovudine | 1 | 1993 | 77 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1993 | 79 | 0.010 |
Why?
| | Disease Progression | 1 | 1999 | 2380 | 0.010 |
Why?
| | Neutrophils | 2 | 1987 | 1176 | 0.010 |
Why?
| | Cell Cycle | 1 | 1994 | 542 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1991 | 217 | 0.010 |
Why?
| | HLA-DP Antigens | 1 | 1991 | 32 | 0.010 |
Why?
| | Thromboxane A2 | 1 | 1990 | 11 | 0.010 |
Why?
| | Immunophenotyping | 1 | 1991 | 274 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 1990 | 116 | 0.010 |
Why?
| | Biological Assay | 1 | 1991 | 112 | 0.010 |
Why?
| | Leukotriene B4 | 1 | 1990 | 48 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 1990 | 150 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1990 | 162 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1990 | 86 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 1990 | 143 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1992 | 383 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1990 | 142 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1990 | 143 | 0.010 |
Why?
| | Epoprostenol | 1 | 1990 | 133 | 0.010 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1992 | 219 | 0.010 |
Why?
| | Coroners and Medical Examiners | 1 | 1989 | 7 | 0.010 |
Why?
| | Virus Cultivation | 1 | 1989 | 25 | 0.010 |
Why?
| | Survival Rate | 1 | 1993 | 1644 | 0.000 |
Why?
| | Adrenal Cortex | 1 | 1988 | 32 | 0.000 |
Why?
| | Methods | 1 | 1988 | 58 | 0.000 |
Why?
| | Arterioles | 1 | 1988 | 39 | 0.000 |
Why?
| | Chemical Fractionation | 1 | 1988 | 28 | 0.000 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 1988 | 79 | 0.000 |
Why?
| | Metaraminol | 1 | 1987 | 1 | 0.000 |
Why?
| | Rats, Inbred WKY | 1 | 1987 | 32 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1987 | 41 | 0.000 |
Why?
| | Peroxidases | 1 | 1987 | 25 | 0.000 |
Why?
| | Mannitol | 1 | 1987 | 32 | 0.000 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1988 | 81 | 0.000 |
Why?
| | Cell Membrane Permeability | 1 | 1987 | 83 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1988 | 293 | 0.000 |
Why?
| | Edetic Acid | 1 | 1987 | 47 | 0.000 |
Why?
| | Propionibacterium | 1 | 1986 | 2 | 0.000 |
Why?
| | AIDS-Related Complex | 1 | 1986 | 3 | 0.000 |
Why?
| | HIV Antigens | 1 | 1987 | 17 | 0.000 |
Why?
| | Mitosis | 1 | 1988 | 164 | 0.000 |
Why?
| | Serum Albumin, Bovine | 1 | 1987 | 61 | 0.000 |
Why?
| | Blood-Brain Barrier | 1 | 1987 | 106 | 0.000 |
Why?
| | Carcinoma | 1 | 1988 | 198 | 0.000 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1986 | 43 | 0.000 |
Why?
| | Argon | 1 | 1986 | 20 | 0.000 |
Why?
| | Cell Division | 1 | 1988 | 758 | 0.000 |
Why?
| | Antigens, Viral | 1 | 1987 | 176 | 0.000 |
Why?
| | Agranulocytosis | 1 | 1986 | 31 | 0.000 |
Why?
| | Homosexuality | 1 | 1986 | 16 | 0.000 |
Why?
| | Hydrogen Peroxide | 1 | 1987 | 288 | 0.000 |
Why?
| | Light | 1 | 1988 | 337 | 0.000 |
Why?
| | Amino Acid Sequence | 1 | 1990 | 1982 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1987 | 424 | 0.000 |
Why?
| | Interleukin-1 | 1 | 1990 | 966 | 0.000 |
Why?
| | Biomarkers, Tumor | 1 | 1992 | 1040 | 0.000 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1985 | 34 | 0.000 |
Why?
| | Brain Neoplasms | 1 | 1993 | 979 | 0.000 |
Why?
| | Pilot Projects | 1 | 1990 | 1373 | 0.000 |
Why?
| | Tissue and Organ Procurement | 1 | 1989 | 228 | 0.000 |
Why?
| | Drug Synergism | 1 | 1986 | 316 | 0.000 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1986 | 161 | 0.000 |
Why?
| | Autoantigens | 1 | 1988 | 396 | 0.000 |
Why?
| | DNA | 1 | 1992 | 1352 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1991 | 951 | 0.000 |
Why?
| | HLA-B27 Antigen | 1 | 1985 | 11 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1990 | 2785 | 0.000 |
Why?
| | Indians, North American | 1 | 1990 | 570 | 0.000 |
Why?
| | Anterior Eye Segment | 1 | 1985 | 9 | 0.000 |
Why?
| | Hyperemia | 1 | 1985 | 45 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1986 | 502 | 0.000 |
Why?
| | Lymphokines | 1 | 1984 | 111 | 0.000 |
Why?
| | Gram-Negative Bacteria | 1 | 1985 | 66 | 0.000 |
Why?
| | Prevalence | 1 | 1990 | 2251 | 0.000 |
Why?
| | Ischemia | 1 | 1987 | 362 | 0.000 |
Why?
| | Monocytes | 1 | 1987 | 504 | 0.000 |
Why?
| | Hodgkin Disease | 1 | 1986 | 121 | 0.000 |
Why?
| | Cryptococcosis | 1 | 1984 | 23 | 0.000 |
Why?
| | alpha 1-Antitrypsin | 1 | 1985 | 103 | 0.000 |
Why?
| | Lymphatic Diseases | 1 | 1983 | 17 | 0.000 |
Why?
| | Clone Cells | 1 | 1984 | 247 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1986 | 520 | 0.000 |
Why?
| | Colitis | 1 | 1986 | 223 | 0.000 |
Why?
| | Pain | 1 | 1988 | 705 | 0.000 |
Why?
| | Meningitis | 1 | 1984 | 74 | 0.000 |
Why?
| | Kidney Transplantation | 1 | 1988 | 541 | 0.000 |
Why?
| | Microscopy, Fluorescence | 1 | 1984 | 396 | 0.000 |
Why?
| | Vasodilation | 1 | 1985 | 419 | 0.000 |
Why?
| | Biomechanical Phenomena | 1 | 1985 | 669 | 0.000 |
Why?
| | Endothelium, Vascular | 1 | 1988 | 847 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1986 | 932 | 0.000 |
Why?
| | Mice, Inbred BALB C | 1 | 1984 | 1144 | 0.000 |
Why?
| | Blood Pressure | 1 | 1987 | 1538 | 0.000 |
Why?
| | Pneumonia, Viral | 1 | 1986 | 338 | 0.000 |
Why?
| | Killer Cells, Natural | 1 | 1983 | 380 | 0.000 |
Why?
| | Sexual Behavior | 1 | 1984 | 440 | 0.000 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1984 | 333 | 0.000 |
Why?
| | Lung | 1 | 1985 | 3561 | 0.000 |
Why?
|
|
Palestine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|